Altasciences Featured Articles

  1. A Changing Paradigm For Non-Rodent Species In Nonclinical Safety Studies 1/7/2025

    The choice of species for nonclinical safety studies is an important step in the drug development process. Check out this scientific journal which outlines vital considerations for species selection.

  2. Nonclinical Studies In Cell and Gene Therapy 1/7/2025

    Looking for best practices and expert tips on how to address challenges and improve study efficiency in nonclinical gene therapy studies? Check out this scientific journal today!

  3. Considerations For Nonclinical Dermal Studies — Advancing To Phase 1 1/7/2025

    We encourage further exploration of dermal drug delivery approaches to enhance therapeutic development, leveraging specialized expertise and minipig models to successfully advance programs to Phase 1 clinical trials.

  4. Managing The Complexities Of Glucagon-Like Peptide-1 Receptor Agonist Drug Development 11/20/2024

    Dive into the dynamic world of GLP-1 receptor agonists, where we explore the current landscape, the challenges ahead and the complexities of early-phase drug development.

  5. Formulation To First Dose: Strategies For Preclinical Success 4/9/2024

    Discover the formulation process for preclinical testing by exploring pre-formulation studies, biopharm assessments, manufacturing, QC, regulatory aspects, and risk management—including a case study.

  6. Proactive Drug Development Solution: Small Molecules 2/1/2024

    Learn how by partnering with Altasciences, pharmaceutical and biotechnology companies can benefit from their expertise and experience to bring better drugs to market more quickly.

  7. Expert Insights On End-To-End Central Nervous System (CNS) Drug Development 1/5/2024

    Altasciences' premier CNS Center of Excellence can help you seamlessly navigate early-phase drug development with expert solutions, saving up to 40% in time along the way.

  8. The Complexities Of Early Phase Ophthalmic Drug Development 1/26/2023

    Discover how the complexity and challenges of bringing ophthalmic therapeutics to market can be mitigated by entrusting your drug development program to an integrated CRO/CDMO partner.